Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
IPO Year:
Exchange: NASDAQ
Website: pluristem.com
Alliance Global Partners initiated coverage of Pluristem Therapeutics with a rating of Buy and set a new price target of $12.50
8-K - Pluri Inc. (0001158780) (Filer)
D - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
10-Q - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
424B5 - Pluri Inc. (0001158780) (Filer)
10-K - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the strategic evolution for our Company. This is our new name. Today, I am proud to share the vision of Pluri: to help pioneer a biotech revolution to create a range of next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity's greatest challenges. In early 2021,
As of July 26, 2022, Pluri's stock will trade under the symbol PLURThe new name reflects the Company's strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainabilityVisit our new Company website: www.pluri-biotech.com HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company, today announced its name change (NASDAQ:PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harness
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) ("Pluristem" or the "Company"), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study. The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of mu
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI) ("Pluristem"), a leading biotechnology company, and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today announced that Pluristem's CEO and President Yaky Yanay and Tnuva Group's Chairman, Haim Gavrieli, will ring the Closing Bell at Nasdaq MarketSite in Times Square, New York. The ceremony, in hon
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiation syndrome (ARS).In 2018, the FDA cleared Pluristem's Investigational New Drug (IND) application for PLX-R18 in the treatment of ARS. HAIFA, Israel, March 23, 2022 (GLOBE NEWSWIRE) -- Pluristem
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company ("Pluristem"), and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat. Eyal Rosenthal, Chief Executive Officer(photo credit: Jim Vetter) Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global ventu
HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay. Dear Shareholders, As I look ahead, I am more confident about the direction of Pluristem than ever before. We believe that our state-of-the-art cell expansion platform has the potential for high demand in the medical field and beyond. Our proven technology is well-positioned to develop high quality cell-based products for a range of emerging industries. This strategy is already bearing fruit – or should I say, meat. We recently clo
Pluristem officially closed a deal with Israel's largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food techPluristem and Tnuva are proven pioneers in cell culture technology and consumer food branding, with 100+ years of combined expertise in their fieldsThe joint venture closes at a pre-money valuation of $40 million, with Tnuva investing $7.5 million HAIFA, Israel, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI) ("Pluristem") and Israel's largest food producer Tnuva Group ("Tnuva") announced today the closing of its landmark collaboration to develop,
HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) (the "Company"), a leading biotechnology company, today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. The analysis is based on 89 patients enrolled in two Phase II studies in the U.S. (the "U.S. study") and in Europe and Israel (collectively, the "EU study" and together with the U.S. study, the "Studies"). The primary efficacy endpoint was the number of ventilator free days (VFD) from day 1
SC 13D - Pluri Inc. (0001158780) (Subject)
SC 13G - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)
SC 13G/A - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)
SC 13G/A - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
3 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
3 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company ("Pluristem"), and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat. Eyal Rosenthal, Chief Executive Officer(photo credit: Jim Vetter) Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global ventu
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market. Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology. She was the founder and Chief Executive Officer of the KSM Institute of Research and Innovation and Mac
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, is pleased to announce the appointment of Ms. Maital Shemesh-Rasmussen, a global health-tech marketing strategist, and Mr. Rami Levi, a leader in global marketing and international governmental affairs, to its Board of Directors. Ms. Maital Shemesh-Rasmussen brings over 20 years of diverse commercialization experience across various industries. Driving growth in the health-tech sector, she has specifically focused on personalized care and patient-centric, data-driven products and valu